Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.
about
mTOR inhibitors in cancer therapyInhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signalingGenetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancerSelective inhibition of RNA polymerase I transcription as a potential approach to treat African trypanosomiasis.Amplified in Breast Cancer Regulates Transcription and Translation in Breast Cancer Cells.Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcriptionThe Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.Therapeutic Approaches Targeting MYC-Driven Prostate CancerAdvanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options.Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.Altered interactions between unicellular and multicellular genes drive hallmarks of transformation in a diverse range of solid tumors.Modeling craniofacial and skeletal congenital birth defects to advance therapies.Proteome complexity and the forces that drive proteome imbalance.TIF-IA: An oncogenic target of pre-ribosomal RNA synthesis.Adaptive Stress Responses During Tumor Metastasis and Dormancy.Conserved nucleolar stress at the onset of cell death.Adenovirus E1A TRRAP-targeting domain-mediated enhancement of MYC association with the NuA4 complex activates a panel of MYC target genes enriched for gene expression and ribosome biogenesis.Stage-dependent therapeutic efficacy in PI3K/mTOR-driven squamous cell carcinoma of the skin.Ribosome biogenesis in cancer: new players and therapeutic avenues.Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers.How the evolution of multicellularity set the stage for cancer.[Ribosomes synthesis at the heart of cell proliferation].Inhibition of Pol I Transcription a New Chance in the Fight Against Cancer.Undermining ribosomal RNA transcription in both the nucleolus and mitochondrion: an offbeat approach to target MYC-driven cancer.A Nucleolar Stress-Specific p53-miR-101 Molecular Circuit Functions as an Intrinsic Tumor-Suppressor Network
P2860
Q28079129-EE08A5EE-2637-409A-BEB6-EB5E0A1B6EE1Q28468631-AB2E1466-2AB1-451B-81FF-EDBD17B14158Q30276619-689B0C8B-03AB-4E80-9193-BD1903DC49EEQ36298245-89B125F8-F01A-4243-B437-337592ED942EQ37218012-DC83C27B-68BB-484C-A66E-5EF296A204CEQ37580133-BD6F0FB4-996F-444B-8A34-2095E3AF5E24Q37631697-4CF2AFC7-FE2D-4968-BADB-1A48D09A9550Q37676253-5BFAC0DE-6797-4432-B555-1BBF1A4CFD05Q37742975-1C83F564-0302-4F48-B9EE-D44AE2D04478Q38685006-017EBC28-097D-4EC3-B9B9-DD4BC946DFAEQ38796992-A1013D13-F870-4E2A-818D-EBF37A5F7348Q38877817-BF77E5E9-59EA-4CAE-B0CA-84A1F4EFF115Q38954697-0B550E28-94B7-466E-B6AB-AC1B89C0B6DCQ38958112-FD31E057-00F2-4B02-A014-86C6AA280738Q39014967-60EB404D-36E9-4980-BFA1-687FA913A3C0Q39272874-EF228B4D-AA0A-479D-8A10-9498E764EB4EQ41927292-4AFD83A9-0A48-40CD-BCCC-E204CD2C5FC8Q47314965-36B86A1C-F2F8-4251-BA67-F81F37B5CA4CQ47344527-EE80AB98-0946-4235-AE82-B06DDB5E207AQ47368952-8038AFD9-39FA-474D-ABCD-71828F8CD41EQ49195059-CB8098B2-481D-4201-B65E-F139E88B5D13Q49485824-97D0486F-4319-4226-96CA-86D67A0EBFDEQ49656307-35B97BE4-CE18-447C-AF4C-0E282F86ECD2Q49706804-56581F95-F86E-47A5-BB75-F28B65C13D9BQ57700801-7D85CA14-ADE2-4E48-8EE0-978C05DB08E8
P2860
Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Combination Therapy Targeting ...... rvival in MYC-Driven Lymphoma.
@en
Combination Therapy Targeting ...... rvival in MYC-Driven Lymphoma.
@nl
type
label
Combination Therapy Targeting ...... rvival in MYC-Driven Lymphoma.
@en
Combination Therapy Targeting ...... rvival in MYC-Driven Lymphoma.
@nl
prefLabel
Combination Therapy Targeting ...... rvival in MYC-Driven Lymphoma.
@en
Combination Therapy Targeting ...... rvival in MYC-Driven Lymphoma.
@nl
P2093
P50
P1433
P1476
Combination Therapy Targeting ...... rvival in MYC-Driven Lymphoma.
@en
P2093
Denis Drygin
Eric Kusnadi
Jennifer R Devlin
Katherine M Hannan
Megan J Bywater
Nadine Hein
Pui Yee Ng
Sean O'Brien
P356
10.1158/2159-8290.CD-14-0673
P50
P577
2015-10-21T00:00:00Z